[go: up one dir, main page]

WO2009025091A1 - Composition pharmaceutique pour le traitement de la fibromyalgie - Google Patents

Composition pharmaceutique pour le traitement de la fibromyalgie Download PDF

Info

Publication number
WO2009025091A1
WO2009025091A1 PCT/JP2008/002282 JP2008002282W WO2009025091A1 WO 2009025091 A1 WO2009025091 A1 WO 2009025091A1 JP 2008002282 W JP2008002282 W JP 2008002282W WO 2009025091 A1 WO2009025091 A1 WO 2009025091A1
Authority
WO
WIPO (PCT)
Prior art keywords
fibromyalgia
pharmaceutical composition
treatment
therapeutic agent
ameliorate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/002282
Other languages
English (en)
Japanese (ja)
Inventor
Kenichi Osada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
St Marianna University School of Medicine
Original Assignee
St Marianna University School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Marianna University School of Medicine filed Critical St Marianna University School of Medicine
Priority to JP2009528958A priority Critical patent/JPWO2009025091A1/ja
Publication of WO2009025091A1 publication Critical patent/WO2009025091A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention porte sur un nouvel agent thérapeutique pour fibromyalgie, une composition thérapeutique comprenant de la tizanidine comme ingrédient actif peut être utilisée comme agent thérapeutique pour la fibromyalgie. La composition pharmaceutique permet d'améliorer une douleur associée à une fibromyalgie et peut également améliorer un trouble du sommeil, une sensation de fatigue et un état dépressif associée à la fibromyalgie et est par conséquent utile comme agent thérapeutique pour la fibromyalgie.
PCT/JP2008/002282 2007-08-23 2008-08-22 Composition pharmaceutique pour le traitement de la fibromyalgie Ceased WO2009025091A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009528958A JPWO2009025091A1 (ja) 2007-08-23 2008-08-22 線維筋痛症治療用医薬組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007216967 2007-08-23
JP2007-216967 2007-08-23

Publications (1)

Publication Number Publication Date
WO2009025091A1 true WO2009025091A1 (fr) 2009-02-26

Family

ID=40378000

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/002282 Ceased WO2009025091A1 (fr) 2007-08-23 2008-08-22 Composition pharmaceutique pour le traitement de la fibromyalgie

Country Status (2)

Country Link
JP (1) JPWO2009025091A1 (fr)
WO (1) WO2009025091A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016111357A1 (fr) * 2015-01-09 2016-07-14 小野薬品工業株式会社 Agent thérapeutique et/ou de prévention contre la fibromyalgie

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030130353A1 (en) * 2001-11-05 2003-07-10 Kranzler Jay D. Methods of treating fibromyalgia
WO2004039383A1 (fr) * 2002-10-31 2004-05-13 Nippon Zoki Pharmaceutical Co., Ltd. Remede contre la fibromyosite

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030130353A1 (en) * 2001-11-05 2003-07-10 Kranzler Jay D. Methods of treating fibromyalgia
WO2004039383A1 (fr) * 2002-10-31 2004-05-13 Nippon Zoki Pharmaceutical Co., Ltd. Remede contre la fibromyosite

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MITSUKO SATO ET AL.: "Sen'ikinsho ni taisuru shinshin igakuteki approach", JAPANESE JOURNAL OF PSYCHOSOMATIC MEDICINE, vol. 45, no. 11, 1 November 2005 (2005-11-01), pages 885 *
MITSUKO SATO ET AL.: "Sen'ikinshu ni taisuru shinshin igakuteki approach", PSYCHOSOMATIC MEDICINE, vol. 8, no. 3, 28 May 2004 (2004-05-28), pages 214 - 219 *
YOSHIFUMI IRIE: "Sen'ikinsho ni keishito ga soko shita 2 rei", KANPO KENKYU, no. 12 GATSUGO, 20 December 2006 (2006-12-20), pages 410 - 413 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016111357A1 (fr) * 2015-01-09 2016-07-14 小野薬品工業株式会社 Agent thérapeutique et/ou de prévention contre la fibromyalgie
US10675275B2 (en) 2015-01-09 2020-06-09 Ono Pharmaceutical Co., Ltd. Prophylactic and/or therapeutic agent for fibromyalgia

Also Published As

Publication number Publication date
JPWO2009025091A1 (ja) 2010-11-18

Similar Documents

Publication Publication Date Title
WO2009056550A3 (fr) Bromhydrate de bupropione et ses applications thérapeutiques
IL201479A (en) Use of tapentadol for the preparation of pain medication
ZA201104600B (en) Use of a foamable composition essentially free of pharmaceutically active ingredients for the treatment of human skin
IL178390A0 (en) Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
WO2009019294A3 (fr) Bromhydrate de bupropion et applications thérapeutiques
MX2010013020A (es) Metodos y composiciones para trastornos del sueño y otros trastornos.
WO2010002283A3 (fr) Nouveaux analogues d’insuline à une activité prolongée
WO2005097119A3 (fr) Inhibiteurs de pten
EP2091540A4 (fr) Dérivés de pyrazolyle à propriétés analgésiques et donc utiles pour le traitement ou la prophylaxie de la douleur
WO2006119958A3 (fr) Utilisation de la flibanserine dans le traitement de la douleur chronique
WO2009040420A3 (fr) Utilisation d'un monoterpène pour accroître une réparation tissulaire
EP2164490A4 (fr) Dérivés de pyrazolyle à propriétés analgésiques et donc utiles dans le traitement ou la prophylaxie de la douleur
IL215840A (en) Arylsulfonamide compounds are converted into two positions 2 and 5, their pharmaceutical composition containing them and their use in the treatment of ccr3-related diseases
IL205290A (en) A variant of human neurorthin protein, or its active biological part, containing medicinal preparations, and its use in the preparation of therapeutic drugs
WO2007083119A3 (fr) Procédés
IL195155A (en) Dosage form for delayed glucocorticoid release and its use in the treatment of rheumatic diseases
WO2007018588A8 (fr) Composition pharmaceutique stable comprenant la forme iv de linézolide
AP2008004379A0 (en) Use of agomelatine in obtaining medicaments intended for the treatment of sleep disorder in the depressed patient
WO2008092219A3 (fr) Composition pharmaceutique comprenant du tramadol et du cétoprofène en association
WO2009025091A1 (fr) Composition pharmaceutique pour le traitement de la fibromyalgie
WO2010075444A3 (fr) Formulations nasales de métoclopramide
WO2008002544A3 (fr) Doses uniques de témozolomide
WO2007105218A3 (fr) Composition et procede de therapie d'une tumeur cerebrale
WO2007135123A3 (fr) Mirtazapine utilisée pour le traitement de la douleur neuropathique
WO2008055092A3 (fr) Administration d'énoxaparine sodique à des patients avec attaque ischémique aiguë

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08790486

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009528958

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08790486

Country of ref document: EP

Kind code of ref document: A1